Interferons, immunity and cancer immunoediting
The DOI matches its Crossref record; 118 of the 119 references it cites were found in a registry or an index.
Abstract
A clear picture of the dynamic relationship between the host immune system and cancer is emerging as the cells and molecules that participate in naturally occurring antitumour immune responses are being identified. The interferons (IFNs) - that is, the type I IFNs (IFNalpha and IFNbeta) and type II IFN (IFNgamma) - have emerged as central coordinators of tumour-immune-system interactions. Indeed, the decade-old finding that IFNgamma has a pivotal role in promoting antitumour responses became the focus for a renewed interest in the largely abandoned concept of cancer immunosurveillance. More recently, type I IFNs have been found to have distinct functions in this process. In this Review, we discuss the roles of the IFNs, not only in cancer immunosurveillance but also in the broader process of cancer immunoediting.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“a cytokine which promotes increased tumour immunogenicity and often used to assess T-cell activation31”
From Stromal senescence establishes an immunosuppressive microenvironment that drives tumorigenesis (2016) · cites this paper as [31]
Citations
Cites
1 retracted
Urisman, A., Molinaro, R. J., Fischer, N., Plummer, S. J., Casey, G., Klein, E. A., Malathi, K., Magi-Galluzzi, C., Tubbs, R. R., Ganem, D., et al. (2006) · PLoS Pathogens · doi:10.1371/journal.ppat.0020025 · Cited by 577 · cited 1×
“However, it remains unclear whether the tumour-suppressor functions of RNaseL depend on IFN”
BackgroundRetractedHanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome
Galon, J., Costes, A., Sanchez-Cabo, F., Kirilovsky, A., Mlecnik, B., Lagorce-Pagès, C., Tosolini, M., Camus, M., Berger, A., Wind, P., et al. (2006) · Science · doi:10.1126/science.1129139 · Cited by 6,516 · cited 1×
“Using a combination of histological and gene-expression analyses, Galon et al”
MethodCancer immunoediting: from immunosurveillance to tumor escape
Dunn, G. P., Bruce, A. T., Ikeda, H., Old, L. J., & Schreiber, R. D. (2002) · Nature Immunology · doi:10.1038/ni1102-991 · Cited by 5,393
Self-citationCancer genes and the pathways they control
Vogelstein, B., & Kinzler, K. W. (2004) · Nature Medicine · doi:10.1038/nm1087 · Cited by 4,249 · cited 1×
“These pathways coordinately defend cells from the oncogenic and/or genotoxic stimuli that can lead to malignant transformatio”
BackgroundHOW CELLS RESPOND TO INTERFERONS
Stark, G. R., Kerr, I. M., Williams, B. R. G., Silverman, R. H., & Schreiber, R. D. (1998) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.67.1.227 · Cited by 3,932 · cited 1×
“Detailed reviews of IFN biology have been published elsewher”
BackgroundSelf-citationMechanisms of type-I- and type-II-interferon-mediated signalling
Platanias, L. C. (2005) · Nature Reviews Immunology · doi:10.1038/nri1604 · Cited by 3,491
The Three Es of Cancer Immunoediting
Dunn, G. P., Old, L. J., & Schreiber, R. D. (2004) · Annual Review of Immunology · doi:10.1146/annurev.immunol.22.012703.104803 · Cited by 3,072
Self-citationThe Immunobiology of Cancer Immunosurveillance and Immunoediting
Dunn, G. P., Old, L. J., & Schreiber, R. D. (2004) · Immunity · doi:10.1016/j.immuni.2004.07.017 · Cited by 3,032
Self-citationIFNγ and lymphocytes prevent primary tumour development and shape tumour immunogenicity
Shankaran, V., Ikeda, H., Bruce, A. T., White, J. M., Swanson, P. E., Old, L. J., & Schreiber, R. D. (2001) · Nature · doi:10.1038/35074122 · Cited by 2,896
Self-citation
Research works printed but not linked: 1
- Yang, J., Murphy, T. L., Ouyang, W. & Murphy, K. M. Induction of interferon-γ production in TH1 CD4+ T cells: evidence for two distinct pathways for promoter activation. Eur. J. Immunol. 29, 548–555 (1999). · DOI · Paper page
Cited by
Immunity, Inflammation, and Cancer
Grivennikov, S. I., Greten, F. R., & Karin, M. (2010) · Cell · doi:10.1016/j.cell.2010.01.025 · Cited by 10,755
“According to the immunosurveillance hypothesis, NK cells and CTLs engage in tumor killing (via perforin, granzyme B, TRAIL or FasL dependent mechanisms), whereas Th1 (by virtue of IFNγ production) and in some instances Th17 cells (via production of IL-17A) provide important help that boosts cytotoxic immunity (Dunn et…”
Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion
Schreiber, R. D., Old, L. J., & Smyth, M. J. (2011) · Science · doi:10.1126/science.1203486 · Cited by 6,474
Self-citationSTATs in cancer inflammation and immunity: a leading role for STAT3
Yu, H., Pardoll, D., & Jove, R. (2009) · Nature reviews. Cancer · doi:10.1038/nrc2734 · Cited by 4,383
Regulation and function of the cGAS–STING pathway of cytosolic DNA sensing
Chen, Q., Sun, L., & Chen, Z. J. (2016) · Nature Immunology · doi:10.1038/ni.3558 · Cited by 2,333
Natural Innate and Adaptive Immunity to Cancer
Vesely, M. D., Kershaw, M. H., Schreiber, R. D., & Smyth, M. J. (2011) · Annual Review of Immunology · doi:10.1146/annurev-immunol-031210-101324 · Cited by 2,101
Self-citationWu, S., Rhee, K.-J., Albesiano, E., Rabizadeh, S., Wu, X., Yen, H.-R., Huso, D. L., Brancati, F. L., Wick, E., McAllister, F., et al. (2009) · Nature Medicine · doi:10.1038/nm.2015 · Cited by 1,812
Stromal gene expression predicts clinical outcome in breast cancer
Finak, G., Bertos, N., Pepin, F., Sadekova, S., Souleimanova, M., Zhao, H., Chen, H., Omeroglu, G., Meterissian, S., Omeroglu, A., et al. (2008) · Nature Medicine · doi:10.1038/nm1764 · Cited by 1,687
The JAK-STAT Pathway: Impact on Human Disease and Therapeutic Intervention
O'Shea, J. J., Schwartz, D. M., Villarino, A. V., Gadina, M., McInnes, I. B., & Laurence, A. (2015) · Annual Review of Medicine · doi:10.1146/annurev-med-051113-024537 · Cited by 1,599
Antigen presentation in cancer: insights into tumour immunogenicity and immune evasion
Jhunjhunwala, S., Hammer, C., & Delamarre, L. (2021) · Nature Reviews Cancer · doi:10.1038/s41568-021-00339-z · Cited by 1,490
Adaptive immunity maintains occult cancer in an equilibrium state
Koebel, C. M., Vermi, W., Swann, J. B., Zerafa, N., Rodig, S. J., Old, L. J., Smyth, M. J., & Schreiber, R. D. (2007) · Nature · doi:10.1038/nature06309 · Cited by 1,436
Self-citationMittal, D., Gubin, M. M., Schreiber, R. D., & Smyth, M. J. (2014) · Current Opinion in Immunology · doi:10.1016/j.coi.2014.01.004 · Cited by 1,471
“Whereas one body of work has clearly established the capacity of chronic inflammation to initiate and promote cancer [1], a second set of studies from other laboratories, including our own, has revealed that an intact immune system can prevent/ control and shape/promote cancer by a process we call ‘Cancer Immunoeditin…”
Self-citationIFNγ: signalling, epigenetics and roles in immunity, metabolism, disease and cancer immunotherapy
Ivashkiv, L. B. (2018) · Nature Reviews Immunology · doi:10.1038/s41577-018-0029-z · Cited by 1,358
DeNardo, D. G., Barreto, J. B., Andreu, P., Vasquez, L., Tawfik, D., Kolhatkar, N., & Coussens, L. M. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.06.018 · Cited by 1,353
“…profiling from breast-cancer-associated stroma revealed a gene signature predictive of good prognostic outcome (>98%, 5 year survival) that was functionally enriched for elements of a T H 1-type immune response, including genes suggestive of CTL and NK cell activity (Finak et al., 2008 ).”
BackgroundCancer to bone: a fatal attraction
Weilbaecher, K. N., Guise, T. A., & McCauley, L. K. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3055 · Cited by 1,285
“Although T lymphocytes have a key role in influencing general tumour growt”
Loss of IFN-γ pathway genes in tumor cells as a mechanism of resistance to anti-CTLA-4 therapy
Gao, J., Shi, L. Z., Zhao, H., Chen, J., Xiong, L., He, Q., Chen, T., Roszik, J., Bernatchez, C., Woodman, S. E., et al. (2016) · Cell · doi:10.1016/j.cell.2016.08.069 · Cited by 1,300
Altered macrophage differentiation and immune dysfunction in tumor development
Sica, A., & Bronte, V. (2007) · Journal of Clinical Investigation · doi:10.1172/jci31422 · Cited by 1,238
Interferon-Gamma at the Crossroads of Tumor Immune Surveillance or Evasion
Castro, F., Cardoso, A. P., Gonçalves, R. M., Serre, K., & Oliveira, M. J. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00847 · Cited by 1,224
“Altogether, these works pave the way for the elaboration of the stepping-stone concept of immunoediting promoted by IFN-γ (195, 196).”
BackgroundImmune checkpoint therapy—current perspectives and future directions
Sharma, P., Goswami, S., Raychaudhuri, D., Siddiqui, B. A., Singh, P., Nagarajan, A., Liu, J., Subudhi, S. K., Poon, C., Gant, K. L., et al. (2023) · Cell · doi:10.1016/j.cell.2023.03.006 · Cited by 1,206
Fuertes, M. B., Kacha, A. K., Kline, J., Woo, S.-R., Kranz, D. M., Murphy, K. M., & Gajewski, T. F. (2011) · Journal of Experimental Medicine · doi:10.1084/jem.20101159 · Cited by 1,192
“Although a role for type I IFNs has been described for immunosurveillance against carcinogen-induced tumors and for rejection of transplanted tumors (Dunn et al., 2005, 2006), the source of type I IFNs and the mechanism of action of this cytokine during the priming phase of an antitumor immune…”
BackgroundImmune cell promotion of metastasis
Kitamura, T., Qian, B.-Z., & Pollard, J. W. (2015) · Nature Reviews Immunology · doi:10.1038/nri3789 · Cited by 1,158
Interferons at age 50: past, current and future impact on biomedicine
Borden, E. C., Sen, G. C., Uze, G., Silverman, R. H., Ransohoff, R. M., Foster, G. R., & Stark, G. R. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2422 · Cited by 1,154
Detection of immunogenic cell death and its relevance for cancer therapy
Fucikova, J., Kepp, O., Kasikova, L., Petroni, G., Yamazaki, T., Liu, P., Zhao, L., Spisek, R., Kroemer, G., & Galluzzi, L. (2020) · Cell Death & Disease · doi:10.1038/s41419-020-03221-2 · Cited by 1,138
Immune infiltration in human tumors: a prognostic factor that should not be ignored
Pagès, F., Galon, J., Dieu-Nosjean, M.-C., Tartour, E., Sautès-Fridman, C., & Fridman, W.-H. (2010) · Oncogene · doi:10.1038/onc.2009.416 · Cited by 1,087
“Furthermore, under the pressure of antitumoral immune activity, selection and outgrowth of variant tumor cells with reduced immunogenicity could occur (Smyth et al., 2001; Dunn et al., 2004, 2006).”
BackgroundSuppression of Antitumor Immunity by Stromal Cells Expressing Fibroblast Activation Protein–α
Kraman, M., Bambrough, P. J., Arnold, J. N., Roberts, E. W., Magiera, L., Jones, J. O., Gopinathan, A., Tuveson, D. A., & Fearon, D. T. (2010) · Science · doi:10.1126/science.1195300 · Cited by 1,134
Indoleamine 2,3-dioxygenase and tumor-induced tolerance
Munn, D. H., & Mellor, A. L. (2007) · Journal of Clinical Investigation · doi:10.1172/jci31178 · Cited by 1,078
“Alternatively, IDO is known to be inducible in many tumor cell lines by IFN-γ and other inflammatory mediators (37); therefore, IDO might be secondarily induced in tumor cells or in host stromal cells in response to inflammatory cytokines from the initial host response against the tumor (76).”
BackgroundDieu-Nosjean, M.-C., Antoine, M., Danel, C., Heudes, D., Wislez, M., Poulot, V., Rabbe, N., Laurans, L., Tartour, E., de Chaisemartin, L., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.0284 · Cited by 1,031
“The density of tumorinfiltrating lymphocytes (TILs) with cytotoxic and memory phenotypes is highly predictive of good clinical outcome.(8-14) However, although prognosis is related to the homing of effector immune cells, it is still unclear where the activation of the specific immune response takes place: in the tumor…”
BackgroundCombining Radiotherapy and Cancer Immunotherapy: A Paradigm Shift
Formenti, S. C., & Demaria, S. (2013) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djs629 · Cited by 1,053
“Likewise, expression of a loss-of-function allele of the purinergic receptor for ATP P2X (7) has been associated with poorer prognosis after treatment (25).”
BackgroundType I interferon is selectively required by dendritic cells for immune rejection of tumors
Diamond, M. S., Kinder, M., Matsushita, H., Mashayekhi, M., Dunn, G. P., Archambault, J. M., Lee, H., Arthur, C. D., White, J. M., Kalinke, U., et al. (2011) · Journal of Experimental Medicine · doi:10.1084/jem.20101158 · Cited by 1,081
“There is strong experimental support for all three phases of cancer immuno editing, elimination, equilibrium, and escape, and many of the key cellular mediators and immune effector molecules involved in host protection from tumor development have been identified (Dunn et al., 2006; Smyth et al., 2006; Koebel et al.,…”
InfluentialSelf-citationMiao, Y., Zhang, Q., Lei, Q., Luo, M., Xie, G., Wang, H., & Guo, A. (2020) · Advanced Science · doi:10.1002/advs.201902880 · Cited by 973
The Inflammatory Response to Cell Death
Rock, K. L., & Kono, H. (2008) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev.pathmechdis.3.121806.151456 · Cited by 912
Weichselbaum, R. R., & Hellman, S. (2011) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2011.44 · Cited by 945
Cytokine patterns in patients with cancer: a systematic review
Lippitz, B. E. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70582-x · Cited by 905
Teng, M. W. L., Bowman, E. P., McElwee, J. J., Smyth, M. J., Casanova, J.-L., Cooper, A. M., & Cua, D. J. (2015) · Nature Medicine · doi:10.1038/nm.3895 · Cited by 873
Burnette, B. C., Liang, H., Lee, Y., Chlewicki, L., Khodarev, N. N., Weichselbaum, R. R., Fu, Y.-X., & Auh, S. L. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-2820 · Cited by 878
“More recently, it has been shown that endogenous type I IFN production plays a critical role in tumor immunoediting (12, 13).”
IL-17 can promote tumor growth through an IL-6–Stat3 signaling pathway
Wang, L., Yi, T., Kortylewski, M., Pardoll, D. M., Zeng, D., & Yu, H. (2009) · Journal of Experimental Medicine · doi:10.1084/jem.20090207 · Cited by 842
“The immune system can act as an extrinsic suppressor of tumors, and the importance of Th1, characterized by IFN- and type 1 IFNs, in inhibiting tumor incidence and growth has been established (Kaplan et al., 1998; Dunn et al., 2006).”
BackgroundResultInfluentialIdentification of essential genes for cancer immunotherapy
Patel, S. J., Sanjana, N. E., Kishton, R. J., Eidizadeh, A., Vodnala, S. K., Cam, M., Gartner, J. J., Jia, L., Steinberg, S. M., Yamamoto, T. N., et al. (2017) · Nature · doi:10.1038/nature23477 · Cited by 870
Tumor-specific Th17-polarized cells eradicate large established melanoma
Muranski, P., Boni, A., Antony, P. A., Cassard, L., Irvine, K. R., Kaiser, A., Paulos, C. M., Palmer, D. C., Touloukian, C. E., Ptak, K., et al. (2008) · Blood · doi:10.1182/blood-2007-11-120998 · Cited by 845
A guide to antigen processing and presentation
Pishesha, N., Harmand, T. J., & Ploegh, H. L. (2022) · Nature Reviews Immunology · doi:10.1038/s41577-022-00707-2 · Cited by 805
m6A mRNA demethylase FTO regulates melanoma tumorigenicity and response to anti-PD-1 blockade
Yang, S., Wei, J., Cui, Y.-H., Park, G., Shah, P., Deng, Y., Aplin, A. E., Lu, Z., Hwang, S., He, C., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-10669-0 · Cited by 743
IFN-γ from lymphocytes induces PD-L1 expression and promotes progression of ovarian cancer
Abiko, K., Matsumura, N., Hamanishi, J., Horikawa, N., Murakami, R., Yamaguchi, K., Yoshioka, Y., Baba, T., Konishi, I., & Mandai, M. (2015) · British Journal of Cancer · doi:10.1038/bjc.2015.101 · Cited by 725
“Once antigen-specific immunity develops, IFN-g is secreted by activated effector T cells (Dunn et al, 2006).”
BackgroundGenetic and biological hallmarks of colorectal cancer
Li, J., Ma, X., Chakravarti, D., Shalapour, S., & DePinho, R. A. (2021) · Genes & Development · doi:10.1101/gad.348226.120 · Cited by 573
“CTLs and Th1 cells are critical contributors to IFN-γ-mediated antitumor immune response (Dunn et al. 2006; Mucida et al. 2013), and NKs have been shown to effectively target cancer cells that lose MHC-I antigens (Vivier et al. 2012).”
BackgroundThe Two Faces of Interferon-γ in Cancer
Zaidi, M. R., & Merlino, G. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0482 · Cited by 593
“Several lines of evidence place IFN-g at the elimination stage of the immunoediting paradigm (62).”
Circulating and disseminated tumour cells — mechanisms of immune surveillance and escape
Mohme, M., Riethdorf, S., & Pantel, K. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.144 · Cited by 602
The anticancer immune response: indispensable for therapeutic success?
Zitvogel, L., Apetoh, L., Ghiringhelli, F., André, F., Tesniere, A., & Kroemer, G. (2008) · Journal of Clinical Investigation · doi:10.1172/jci35180 · Cited by 573
Jablonska, J., Leschner, S., Westphal, K., Lienenklaus, S., & Weiss, S. (2010) · Journal of Clinical Investigation · doi:10.1172/jci37223 · Cited by 564
Zhang, J.-P., Yan, J., Xu, J., Pang, X.-H., Chen, M.-S., Li, L., Wu, C., Li, S.-P., & Zheng, L. (2009) · Journal of Hepatology · doi:10.1016/j.jhep.2008.12.033 · Cited by 535
“IFN-c is necessary for cytotoxic effector functions and has anti-angiogenic effects in most tumor models [33].”
BackgroundLiakou, C. I., Kamat, A., Tang, D. N., Chen, H., Sun, J., Troncoso, P., Logothetis, C., & Sharma, P. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0806075105 · Cited by 549
“These data indicate that a major impact of CTLA-4 blockade in cancer patients was the expansion, both within the blood and the tumor itself, of a subpopulation of CD4 T cells that expressed high levels of ICOS and secreted IFN , a cytokine which that is known to play a role in antitumor responses (23, 24).”
Cata, J. P., Wang, H., Gottumukkala, V., Reuben, J., & Sessler, D. I. (2013) · British Journal of Anaesthesia · doi:10.1093/bja/aet068 · Cited by 539
Therapeutic targets and biomarkers of tumor immunotherapy: response versus non-response
Wang, D.-R., Wu, X.-L., & Sun, Y.-L. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01136-2 · Cited by 501
Barkley, D., Moncada, R., Pour, M., Liberman, D. A., Dryg, I., Werba, G., Wang, W., Baron, M., Rao, A., Xia, B., et al. (2022) · Nature Genetics · doi:10.1038/s41588-022-01141-9 · Cited by 532
Cancer Immunotherapy by Dendritic Cells
Melief, C. J. M. (2008) · Immunity · doi:10.1016/j.immuni.2008.08.004 · Cited by 508
“…cancer, such as the presence of various types of suppressive leukocytes with or without constitutive P-STAT3 signaling (see above), immunoediting (Dunn et al., 2006; Koebel et al., 2007), abnormal tumor vasculature inhibiting effector T cell entry (Hamzah et al., 2008a; Hamzah et al., 2008b), or…”
BackgroundDisis, M. L. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.2146 · Cited by 489
“T cells that secrete cytokines such as interferon gamma (IFN- ) generate acute inflammation that results in expansion of cytotoxic T cells (CTLs), tissue destruction, and the potential control or even elimination of cancer.(2) The tissuedestructive properties of this type of inflammatory response are consistent with w…”
BackgroundImmune surveillance: a balance between protumor and antitumor immunity
Ostrand-Rosenberg, S. (2008) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2007.12.007 · Cited by 480
Inflammatory networks underlying colorectal cancer
Lasry, A., Zinger, A., & Ben-Neriah, Y. (2016) · Nature Immunology · doi:10.1038/ni.3384 · Cited by 489
Chen, D., Xie, J., Fiskesund, R., Dong, W., Liang, X., Lv, J., Jin, X., Liu, J., Mo, S., Zhang, T., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-03225-9 · Cited by 489
Stromal senescence establishes an immunosuppressive microenvironment that drives tumorigenesis
Ruhland, M. K., Loza, A. J., Capietto, A.-H., Luo, X., Knolhoff, B. L., Flanagan, K. C., Belt, B. A., Alspach, E., Leahy, K., Luo, J., et al. (2016) · Nature Communications · doi:10.1038/ncomms11762 · Cited by 496
Silencing of Irf7 pathways in breast cancer cells promotes bone metastasis through immune escape
Bidwell, B. N., Slaney, C. Y., Withana, N. P., Forster, S., Cao, Y., Loi, S., Andrews, D., Mikeska, T., Mangan, N. E., Samarajiwa, S. A., et al. (2012) · Nature Medicine · doi:10.1038/nm.2830 · Cited by 487
Kopp, H.-G., Placke, T., & Salih, H. R. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-2123 · Cited by 469
“malignant cells with the immune system and seems to require induction of tolerance of innate and adaptive immune effector cells (25, 26).”
BackgroundTumour-associated mesenchymal stem/stromal cells: emerging therapeutic targets
Shi, Y., Du, L., Lin, L., & Wang, Y. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.193 · Cited by 460
Resistance Mechanisms to Anti-PD Cancer Immunotherapy
Vesely, M. D., Zhang, T., & Chen, L. (2022) · Annual Review of Immunology · doi:10.1146/annurev-immunol-070621-030155 · Cited by 468
The Adaptive Immunologic Microenvironment in Colorectal Cancer: A Novel Perspective
Galon, J., Fridman, W.-H., & Pagès, F. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-4806 · Cited by 447
“prevented from expanding by immune pressure (18)].”
Radiotherapy Promotes Tumor-Specific Effector CD8+ T Cells via Dendritic Cell Activation
Gupta, A., Probst, H. C., Vuong, V., Landshammer, A., Muth, S., Yagita, H., Schwendener, R., Pruschy, M., Knuth, A., & van den Broek, M. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1200563 · Cited by 446
Conlon, J., Burdette, D. L., Sharma, S., Bhat, N., Thompson, M., Jiang, Z., Rathinam, V. A. K., Monks, B., Jin, T., Xiao, T. S., et al. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1300097 · Cited by 434
Cell-cell communication: New insights and clinical implications
Su, J., Song, Y., Zhu, Z., Huang, X., Fan, J., Qiao, J., & Mao, F. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01888-z · Cited by 433
Salcedo, R., Worschech, A., Cardone, M., Jones, Y., Gyulai, Z., Dai, R.-M., Wang, E., Ma, W., Haines, D., O'hUigin, C., et al. (2010) · Journal of Experimental Medicine · doi:10.1084/jem.20100199 · Cited by 429
“…and Il18/ mice to colon carcinogenesis might exclusively be the result of the lack of an immunosurveillance effect of adaptive immunity and IFN- (Dunn et al., 2006), particularly when it is considered that Rag/ immunodeficient mice have reduced rather than increased susceptibility to colon…”
BackgroundSchabath, M. B., Welsh, E. A., Fulp, W. J., Chen, L., Teer, J. K., Thompson, Z. J., Engel, B. E., Xie, M., Berglund, A. E., Creelan, B. C., et al. (2016) · Oncogene · doi:10.1038/onc.2015.375 · Cited by 416
“It is now well established that a functional immune system is crucial in controlling tumor growth (27–29).”
Genard, G., Lucas, S., & Michiels, C. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00828 · Cited by 419
“The most famous one is IFNγ (83), approved by the FDA.”
BackgroundInfluentialGuo, Y., Wang, D., Song, Q., Wu, T., Zhuang, X., Bao, Y., Kong, M., Qi, Y., Tan, S., & Zhang, Z. (2015) · ACS Nano · doi:10.1021/acsnano.5b01042 · Cited by 413
IL-10 Elicits IFNγ-Dependent Tumor Immune Surveillance
Mumm, J. B., Emmerich, J., Zhang, X., Chan, I., Wu, L., Mauze, S., Blaisdell, S., Basham, B., Dai, J., Grein, J., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.11.003 · Cited by 418
Indoleamine 2,3‐dioxygenase in T‐cell tolerance and tumoral immune escape
Katz, J. B., Muller, A. J., & Prendergast, G. C. (2008) · Immunological Reviews · doi:10.1111/j.1600-065x.2008.00610.x · Cited by 398
“These more rigorous studies have corroborated the notion that, in fact, immunodeficient mice do develop more spontaneous and carcinogen-induced tumors than their immunocompetent counterparts (2).”
BackgroundResultSuppression of autophagy by FIP200 deletion inhibits mammary tumorigenesis
Wei, H., Wei, S., Gan, B., Peng, X., Zou, W., & Guan, J.-L. (2011) · Genes & Development · doi:10.1101/gad.2051011 · Cited by 401
“Similar to findings in other autophagy-deficient cells by inactivation of various autophagy genes (Komatsu et al. 2005; Nakai et al. 2007; Ebato et al. 2008), we also detected an increased number of mitochondria per nucleus in FIP200-null mammary tumor cells (25 6 3) compared with that in Ctrl-MT…”
ResultLymph node colonization induces tumor-immune tolerance to promote distant metastasis
Reticker-Flynn, N. E., Zhang, W., Belk, J. A., Basto, P. A., Escalante, N. K., Pilarowski, G. O. W., Bejnood, A., Martins, M. M., Kenkel, J. A., Linde, I. L., et al. (2022) · Cell · doi:10.1016/j.cell.2022.04.019 · Cited by 385
Innate immune mechanisms of colitis and colitis-associated colorectal cancer
Saleh, M., & Trinchieri, G. (2011) · Nature Reviews Immunology · doi:10.1038/nri2891 · Cited by 403
“Thus, the AOM plus DSS-enhanced tumorigenic phenotype in MYD88- or inflammasome-deficient mice, which express reduced IFNγ levels, might be partially due to impaired tumour immunosurveillanc”
BackgroundImmune-mediated dormancy: an equilibrium with cancer
Teng, M. W. L., Swann, J. B., Koebel, C. M., Schreiber, R. D., & Smyth, M. J. (2008) · Journal of Leukocyte Biology · doi:10.1189/jlb.1107774 · Cited by 359
“Subsequently, mice lacking an intact IFN- receptor were found to have an increased incidence of spontaneous and carcinogen-induced tumors compared with age-matched, wildtype mice [5, 6]. Although IFN- has been shown to play multiple roles in promoting protective host responses against carcinogen-induced tumors [ 7 ],…”
Self-citationHistorical review of the causes of cancer
Blackadar, C. B. (2016) · World Journal of Clinical Oncology · doi:10.5306/wjco.v7.i1.54 · Cited by 389
Tumor-induced perturbations of cytokines and immune cell networks
Burkholder, B., Huang, R.-Y., Burgess, R., Luo, S., Jones, V. S., Zhang, W., Lv, Z.-Q., Gao, C.-Y., Wang, B.-L., Zhang, Y.-M., et al. (2014) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2014.01.004 · Cited by 356
Type I interferon response and innate immune sensing of cancer
Fuertes, M. B., Woo, S.-R., Burnett, B., Fu, Y.-X., & Gajewski, T. F. (2013) · Trends in Immunology · doi:10.1016/j.it.2012.10.004 · Cited by 375
Donadi, E. A., Castelli, E. C., Arnaiz-Villena, A., Roger, M., Rey, D., & Moreau, P. (2011) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-010-0580-7 · Cited by 362
“Third, variants that no longer respond to the host immune system are maintained [183–185].”
BackgroundGangoso, E., Southgate, B., Bradley, L., Rus, S., Galvez-Cancino, F., McGivern, N., Güç, E., Kapourani, C.-A., Byron, A., Ferguson, K. M., et al. (2021) · Cell · doi:10.1016/j.cell.2021.03.023 · Cited by 359
“IFN signaling has a well-recognized role in orchestrating antitumor responses (Dunn et al., 2006).”
Targeting a neoantigen derived from a common TP53 mutation
Hsiue, E. H.-C., Wright, K. M., Douglass, J., Hwang, M. S., Mog, B. J., Pearlman, A. H., Paul, S., DiNapoli, S. R., Konig, M. F., Wang, Q., et al. (2021) · Science · doi:10.1126/science.abc8697 · Cited by 367
Tumor-derived IFN triggers chronic pathway agonism and sensitivity to ADAR loss
Liu, H., Golji, J., Brodeur, L. K., Chung, F. S., Chen, J. T., deBeaumont, R. S., Bullock, C. P., Jones, M. D., Kerr, G., Li, L., et al. (2019) · Nature Medicine · doi:10.1038/s41591-018-0302-5 · Cited by 349
TCR-engineered T cells targeting E7 for patients with metastatic HPV-associated epithelial cancers
Nagarsheth, N. B., Norberg, S. M., Sinkoe, A. L., Adhikary, S., Meyer, T. J., Lack, J. B., Warner, A. C., Schweitzer, C., Doran, S. L., Korrapati, S., et al. (2021) · Nature Medicine · doi:10.1038/s41591-020-01225-1 · Cited by 345
Th9 cells promote antitumor immune responses in vivo
Lu, Y., Hong, S., Li, H., Park, J., Hong, B., Wang, L., Zheng, Y., Liu, Z., Xu, J., He, J., et al. (2012) · Journal of Clinical Investigation · doi:10.1172/jci65459 · Cited by 361
“Th1 cells have traditionally been regarded as most efficient in tumor rejection among the subsets of Th cells (4, 5).”
Interferon gamma in cancer immunotherapy
Ni, L., & Lu, J. (2018) · Cancer Medicine · doi:10.1002/cam4.1700 · Cited by 360
Differential immune system DNA methylation and cytokine regulation in post-traumatic stress disorder
Smith, A. K., Conneely, K. N., Kilaru, V., Mercer, K. B., Weiss, T. E., Bradley, B., Tang, Y., Gillespie, C. F., Cubells, J. F., & Ressler, K. J. (2011) · American Journal of Medical Genetics Part B: Neuropsychiatric Genetics · doi:10.1002/ajmg.b.31212 · Cited by 355
“TNFα crosses the blood–brain barrier to stimulate the HPA axis, resulting in increased production of cortisol and symptoms including malaise, fatigue, and changes in sleep and appetite [Raison and Miller 2003; Silverman et al., 2005; Dunn et al., 2006; Sternberg 2006].”
BackgroundHe, D., Li, H., Yusuf, N., Elmets, C. A., Li, J., Mountz, J. D., & Xu, H. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0902574 · Cited by 334
Moving towards personalized treatments of immune-related adverse events
Esfahani, K., Elkrief, A., Calabrese, C., Lapointe, R., Hudson, M., Routy, B., Miller, W. H., & Calabrese, L. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0352-8 · Cited by 351
Atlas of the plasma proteome in health and disease in 53,026 adults
Deng, Y.-T., You, J., He, Y., Zhang, Y., Li, H.-Y., Wu, X.-R., Cheng, J.-Y., Guo, Y., Long, Z.-W., Chen, Y.-L., et al. (2025) · Cell · doi:10.1016/j.cell.2024.10.045 · Cited by 294
Roles of unphosphorylated STATs in signaling
Yang, J., & Stark, G. R. (2008) · Cell Research · doi:10.1038/cr.2008.41 · Cited by 347
Zheng, H., Zhao, W., Yan, C., Watson, C. C., Massengill, M., Xie, M., Massengill, C., Noyes, D. R., Martinez, G. V., Afzal, R., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2584 · Cited by 340
“4H), consistentwith a feed-forward signaling pathwaywhere production of IFNg by T cells enhances tumor cell immunogenicity (31), in turn further enhancing T-cell recruitment and function.”
BackgroundRegulation of TLR7/9 responses in plasmacytoid dendritic cells by BST2 and ILT7 receptor interaction
Cao, W., Bover, L., Cho, M., Wen, X., Hanabuchi, S., Bao, M., Rosen, D. B., Wang, Y.-H., Shaw, J. L., Du, Q., et al. (2009) · Journal of Experimental Medicine · doi:10.1084/jem.20090547 · Cited by 313
“Because IFN- is well known to be required for deterring the growth of primary tumors (Wenzel et al., 2005; Dunn et al., 2006), BST2– ILT7 interactions that suppress pDCs’ IFN responses may contribute to the tumor tolerance (Fig.”
BackgroundRakhra, K., Bachireddy, P., Zabuawala, T., Zeiser, R., Xu, L., Kopelman, A., Fan, A. C., Yang, Q., Braunstein, L., Crosby, E., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.10.002 · Cited by 339
“Oncogene addiction is associated with proliferative arrest, apoptosis, differentiation, and cellular senescence as well as the shutdown of host programs such as angiogenesis (Felsher, 2003; Felsher and Bishop, 1999; Giuriato et al., 2006; Jain et al., 2002; Shachaf et al., 2004; Wu et al., 2007).”
BackgroundMajoros, A., Platanitis, E., Kernbauer-Hölzl, E., Rosebrock, F., Müller, M., & Decker, T. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00029 · Cited by 325
“Immunostimulatory activities of IFN-I also contribute to immunosurveillance against cancer (11).”
BackgroundZhang, M., Liu, C., Tu, J., Tang, M., Ashrafizadeh, M., Nabavi, N., Sethi, G., Zhao, P., & Liu, S. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02305-x · Cited by 259
Prolonged activation of innate immune pathways by a polyvalent STING agonist
Li, S., Luo, M., Wang, Z., Feng, Q., Wilhelm, J., Wang, X., Li, W., Wang, J., Cholka, A., Fu, Y.-X., et al. (2021) · Nature Biomedical Engineering · doi:10.1038/s41551-020-00675-9 · Cited by 317
Coordination of Intratumoral Immune Reaction and Human Colorectal Cancer Recurrence
Camus, M., Tosolini, M., Mlecnik, B., Pagès, F., Kirilovsky, A., Berger, A., Costes, A., Bindea, G., Charoentong, P., Bruneval, P., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-2654 · Cited by 306
“Furthermore, under the pressure of antitumoral immune activity, selection and outgrowth of variant tumor cells with reduced immunogenicity could occur (8, 22, 23).”
BackgroundEngineering strategies to enhance oncolytic viruses in cancer immunotherapy
Tian, Y., Xie, D., & Yang, L. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-00951-x · Cited by 293
Cancer immunosurveillance, immunoediting and inflammation: independent or interdependent processes?
Bui, J. D., & Schreiber, R. D. (2007) · Current Opinion in Immunology · doi:10.1016/j.coi.2007.02.001 · Cited by 303
“New players in the cancer immunoediting process: NKG2D, IFNa/b and IL-23 A comprehensive list of immune cells and molecules involved in cancer immunoediting is reviewed elsewhere [2,5 ,9]; this includes a cast of performers such as ab T cells, gd T cells, natural killer T cells, natural killer (NK) cells, signal trans…”
BackgroundSelf-citationKenter, G. G., Welters, M. J. P., Valentijn, A. R. P. M., Löwik, M. J. G., Berends-van der Meer, D. M. A., Vloon, A. P. G., Drijfhout, J. W., Wafelman, A. R., Oostendorp, J., Fleuren, G. J., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1881 · Cited by 315
Mouse models of metastasis: progress and prospects
Gómez-Cuadrado, L., Tracey, N., Ma, R., Qian, B., & Brunton, V. G. (2017) · Disease Models & Mechanisms · doi:10.1242/dmm.030403 · Cited by 301
“Immune rejection is a key factor that limits the efficiency of tumor engraftment in immune-competent preclinical models, even when the tumor and host are both from the same syngeneic background (Dunn et al., 2006).”
Background
Metadata
- Authors
- Dunn, G. P., Koebel, C. M., & Schreiber, R. D.
- Affiliations
- Washington University in St. Louis (US)
- Corresponding author
- Schreiber, Robert D.
- Venue
- Nature Reviews Immunology
- Published
- 2006-11
- Volume
- 6
- Issue
- 11
- Pages
- 836-848
- ISSN
- 1474-1733 (ISSN-L)
- 1474-1741
- OpenAlex
- W2052313621
- Cited by
- 1,617
- References
- 119
- Citations by year
- 2026: 33 · 2025: 51 · 2024: 87 · 2023: 104 · 2022: 84 · 2021: 94 · 2020: 93 · 2019: 73 · 2018: 85 · 2017: 74 · 2016: 93 · 2015: 100 · 2014: 100 · 2013: 79 · 2012: 76
- FWCI
- 4.99
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature reviews. Immunology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Cancer Institute
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › interferon and immune responses
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Keywords
- interferon, type I interferon, interferon-gamma, cancer immunoediting, tumor surveillance, antitumor immunity, tumor-immune interactions, interferon-alpha, interferon-beta, cancer immunotherapy
- MeSH terms
- Animals, Humans, Immunity, Immunotherapy, Interferons, Neoplasms, Monitoring, Immunologic, Signal Transduction
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.